Axovant spinoff Arvelle Therapeutics received $180m in the LSP-led series A round, and will focus on the development of a recently licensed epilepsy drug.

Nan Fung-backed mitochondrial therapy developer Stealth BioTherapeutics floated at the foot of its range to raise $78m, having disclosed $100m in financing last June.

University of Liverpool, Liverpool John Moores and Liverpool City Council will launch the Sciontec Liverpool fund to drive works for the city’s $2.6bn Knowledge Quarter Liverpool project.

The liver disease diagnostics spinout has secured the first tranche of a $10m series A investment by Fosun Pharma initially announced in October 2018.

State lawmakers are considering plans to fund supports for Maryland’s cybersecurity and life sciences sectors administered by local economic development agency Tedco.

Passage Bio will develop therapies for diseases affecting the central nervous system based on research by James Wilson at Penn, after raising almost $116m in a series A round.

Commercialisation firm NetScientific will delist from Aim to free up cash for its portfolio companies, having failed to attract concrete offers after putting itself up for an acquisition.

Passage Bio has launched to develop treatments for diseases affecting the central nervous system, after raising almost $116m in a series A round backed by Lilly Asia Ventures.

CK Hutchinson's Longliv fund has made its first investment, leading the medical diagnostic system producer's $27.8m series C round.

Osage University Partners has contributed to a series A round for Vor Biopharma, an oncology drug developer based on work by Siddhartha Mukherjee at Columbia University.